Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound

April 28, 2026 06:26 AM EDTUpdated 11:17 AM R&D Boehringer, Zealand’s obe­si­ty shot looks as good as We­govy, but weak­er than Zep­bound Elizabeth Cairns Senior biopharma journalist Obe­si­ty pa­tients tak­ing the weight loss in­jec­tion be­ing de­vel­oped by Boehringer In­gel­heim lost near­ly 17% of their weight af­ter about a year and a half … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER